Rituximab Biosimilar PF-05280586

Known as: PF-05280586 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2018
01220142018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
OBJECTIVE This extension study provided continued treatment to subjects with active rheumatoid arthritis who had participated for… (More)
Is this relevant?
2018
2018
PURPOSE With the introduction of biosimilars of anticancer monoclonal antibodies (mAbs) in oncology, physicians are potentially… (More)
Is this relevant?
2016
2016
AIMS Pharmacokinetic (PK) similarity was assessed among PF-05280586 (a proposed biosimilar) vs. rituximab sourced from the… (More)
Is this relevant?
2016
2016
AIMS To evaluate potential differences between PF-05280586 and rituximab sourced from the European Union (rituximab-EU) and USA… (More)
Is this relevant?
2014
2014
Comparative nonclinical studies were conducted with the proposed biosimilar PF-05280586 and rituximab-EU (MabThera®). In side-by… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?